Patient survival and its relation to tumor absorbed dose in [ 177 Lu]Lu-DOTA-TATE therapy of neuroendocrine Tumours (EANM 2026) - Sep 29, 2026 - Abstract #EP-0885; "Mean tumor AD to the entire tumor burden is an independent predictor of survival in patients with G1-G2 NETs treated with [177Lu]Lu-DOTA-TATE. These findings support the use of tumor dosimetry in treatment planning and suggest that a target AD of around 118 Gy is clinically relevant."
Clinical • Neuroendocrine Tumor • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
C. Warfvinge; S. Curkic Kapidzic; J. Gustafsson; L. Jessen; J. Svensson; A. Sundlöv; K. Sjögreen Gleisner
|